Taysha Gene Therapies, Inc. (TSHA)
| Market Cap | 1.68B +117.8% |
| Revenue (ttm) | 5.49M -32.3% |
| Net Income | -149.63M |
| EPS | -0.41 |
| Shares Out | 325.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,305,666 |
| Open | 5.11 |
| Previous Close | 5.04 |
| Day's Range | 5.08 - 5.22 |
| 52-Week Range | 2.71 - 7.30 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+151.94%) |
| Est. Earnings | Nov 3, 2026 |
About TSHA
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-... [Read more]
Financial Performance
In 2025, Taysha Gene Therapies's revenue was $9.77 million, an increase of 17.28% compared to the previous year's $8.33 million. Losses were -$109.00 million, 22.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TSHA stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 151.94% from the latest price.
News
Taysha Gene Therapies initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Taysha Gene Therapies (TSHA) with an Outperform rating.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-...
Taysha Gene Therapies Earnings Call Transcript: Q2 2026
Key milestones included completion of dosing in pivotal trials, strong long-term efficacy and safety data, and a $230M financing extending cash runway into 2H 2028. Payer research supports robust reimbursement potential for TSHA-102, with BLA submission and pivotal data expected in 1H 2027.
Taysha Gene Therapies Earnings release: Q2 2026
Taysha Gene Therapies released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Taysha Gene Therapies Quarterly report: Q2 2026
Taysha Gene Therapies has published its Q2 2026 quarterly earnings report on August 11, 2026.
Taysha Gene Therapies reports Q2 EPS (13c), consensus (11c)
“During the second quarter, we continued to execute against our clinical development strategy for TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a potent...
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA s...
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies, Catalent announce commercial supply pact for TSHA-102
Taysha Gene Therapies (TSHA) and Catalent announced a commercial supply agreement for TSHA-102, Taysha’s investigational gene therapy in pivotal development for Rett syndrome, under which Catalent wil...
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla.
Taysha Gene Therapies price target raised to $13 from $11 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Taysha Gene Therapies (TSHA) to $13 from $11 and keeps a Buy rating on the shares.
Taysha Gene Therapies falls -11.0%
Taysha Gene Therapies (TSHA) is down -11.0%, or -70c to $5.64.
Taysha Gene Therapies Slides: Corporate presentation
Taysha Gene Therapies has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Taysha Gene Therapies price target raised to $15 from $12 at Baird
Baird raised the firm’s price target on Taysha Gene Therapies (TSHA) to $15 from $12 and keeps an Outperform rating on the shares. The firm updated its model as they…
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity
Taysha Gene Therapies management to meet with Piper Sandler
Meeting to be held in Minneapolis on June 30 hosted by Piper Sandler.
Taysha Gene Therapies 32.5M share Spot Secondary priced at $6.00
The deal priced below last closing price of $6.94. Baird is acting as sole book running manager for the offering.
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies announces $200M common stock offering
Taysha Gene Therapies (TSHA) announced that it has commenced an underwritten public offering of $200M shares of its common stock and, in lieu of common stock to certain investors that…
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-b...
Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital
BMO Capital analyst Keith Tapper raised the firm’s price target on Taysha Gene Therapies (TSHA) to $14 from $10 and keeps an Outperform rating on the shares after the company…
Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital
BMO Capital analyst Keith Tapper raised the firm’s price target on Taysha Gene Therapies (TSHA) to $14 from $10 and keeps an Outperform rating on the shares after the company…
Taysha Gene Therapies price target raised to $10 from $9 at BofA
BofA raised the firm’s price target on Taysha Gene Therapies (TSHA) to $10 from $9 and keeps a Buy rating on the shares after the company reported an update for…
Taysha Gene Therapies price target raised to $11 from $8 at Citizens
Citizens raised the firm’s price target on Taysha Gene Therapies (TSHA) to $11 from $8 and keeps an Outperform rating on the shares. Updated REVEAL Part A data from Taysha…
Taysha Gene Therapies Transcript: Study result
Dosing is complete in the pivotal REVEAL trial for TSHA-102 in Rett syndrome, with 100% of patients achieving developmental milestones and significant, durable gains. TSHA-102 was well-tolerated, and the FDA supports a potential BLA submission based on six-month interim data. Top-line data and FDA feedback are expected in H1 2027.